Calamos Advisors LLC Invests $529,000 in Vera Therapeutics, Inc. $VERA

Calamos Advisors LLC purchased a new stake in shares of Vera Therapeutics, Inc. (NASDAQ:VERA) during the 1st quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm purchased 13,146 shares of the company’s stock, valued at approximately $529,000.

Several other institutional investors and hedge funds have also recently made changes to their positions in VERA. GAMMA Investing LLC boosted its stake in shares of Vera Therapeutics by 50.5% during the fourth quarter. GAMMA Investing LLC now owns 703 shares of the company’s stock valued at $36,000 after purchasing an additional 236 shares in the last quarter. Los Angeles Capital Management LLC bought a new position in shares of Vera Therapeutics in the 4th quarter worth $46,000. Quantbot Technologies LP purchased a new stake in shares of Vera Therapeutics during the 2nd quarter worth $51,000. Aster Capital Management DIFC Ltd purchased a new stake in shares of Vera Therapeutics during the 4th quarter worth $71,000. Finally, Tower Research Capital LLC TRC lifted its position in shares of Vera Therapeutics by 192.9% during the second quarter. Tower Research Capital LLC TRC now owns 4,186 shares of the company’s stock valued at $99,000 after buying an additional 2,757 shares during the last quarter. 99.21% of the stock is currently owned by institutional investors.

Vera Therapeutics Price Performance

VERA stock opened at $38.50 on Friday. The business has a fifty day moving average of $37.14 and a two-hundred day moving average of $40.64. The company has a quick ratio of 13.64, a current ratio of 13.64 and a debt-to-equity ratio of 0.15. The stock has a market cap of $2.76 billion, a price-to-earnings ratio of -6.95 and a beta of 0.92. Vera Therapeutics, Inc. has a 52-week low of $19.07 and a 52-week high of $56.05.

Vera Therapeutics (NASDAQ:VERA) last issued its quarterly earnings results on Thursday, May 7th. The company reported ($1.69) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.33) by ($0.36). During the same period last year, the business earned ($0.81) EPS. As a group, research analysts anticipate that Vera Therapeutics, Inc. will post -6.37 earnings per share for the current year.

Insider Buying and Selling

In related news, CEO Marshall Fordyce sold 46,250 shares of the firm’s stock in a transaction that occurred on Tuesday, July 7th. The stock was sold at an average price of $42.30, for a total transaction of $1,956,375.00. Following the transaction, the chief executive officer owned 151,994 shares in the company, valued at $6,429,346.20. This trade represents a 23.33% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last quarter, insiders have sold 83,250 shares of company stock worth $3,337,770. 15.90% of the stock is owned by company insiders.

Wall Street Analyst Weigh In

Several brokerages recently issued reports on VERA. William Blair reaffirmed an “outperform” rating on shares of Vera Therapeutics in a research report on Tuesday, June 2nd. Wedbush upped their price target on shares of Vera Therapeutics from $35.00 to $43.00 and gave the company a “neutral” rating in a research note on Wednesday, July 8th. TD Cowen lifted their price objective on shares of Vera Therapeutics from $73.00 to $78.00 and gave the stock a “buy” rating in a research note on Wednesday, July 8th. Guggenheim raised their target price on Vera Therapeutics from $56.00 to $76.00 and gave the stock a “buy” rating in a research note on Wednesday, July 8th. Finally, Jefferies Financial Group restated a “buy” rating and issued a $60.00 price objective on shares of Vera Therapeutics in a research note on Tuesday, June 2nd. Eleven investment analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat, Vera Therapeutics has a consensus rating of “Moderate Buy” and an average target price of $84.58.

Vera Therapeutics Company Profile

Vera Therapeutics is a clinical-stage biotechnology company focused on developing novel immunotherapies that harness the body’s own regulatory T cells to treat autoimmune and inflammatory diseases. By leveraging a proprietary protein engineering platform, the company designs Treg-selective cytokine variants intended to restore immune balance and provide targeted, disease-modifying effects. Its pipeline comprises multiple preclinical and clinical candidates aimed at indications characterized by chronic inflammation and autoimmunity.

Founded in 2018 and headquartered in Cambridge, Massachusetts, Vera Therapeutics collaborates with leading academic and research institutions to advance its development programs.